Status:
TERMINATED
Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation
Lead Sponsor:
State University of New York at Buffalo
Collaborating Sponsors:
IRIDEX Corporation
Conditions:
Glaucoma
Eligibility:
All Genders
18-89 years
Phase:
NA
Brief Summary
This is a prospective study to evaluate the clinical outcome of varying doses of Micropulse TransScleral CycloPhotocoagulation (MP-TSCPC) laser in patients with glaucoma. The study will assess documen...
Detailed Description
Glaucoma is a condition where an increase in the accumulation of aqueous humor inside the anterior chamber of the eye results in raised intraocular pressure (IOP), visual field defects and cupping of ...
Eligibility Criteria
Inclusion
- Decision to treat by MP-TSCPC Laser
- Patients diagnosed with Glaucoma
- Patients aged 18 years old and above
- Glaucoma that is inadequately controlled on medical therapy
- Patients with primary open angle glaucoma with or without previously failed trabeculectomy or other aqueous drainage surgical procedures
Exclusion
- Patients age less than 18 years
- Patients unable or unwilling to provide informed consent to participate in the study
- Patients potentially unavailable for follow up visits
- Patients with significant scleral thinning
- Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study
- Albino patients that have no iris pigmentation
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 11 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04709679
Start Date
January 1 2021
End Date
October 11 2021
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ira G. Ross Eye Institute
Buffalo, New York, United States, 14209